Status:
COMPLETED
Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer
Lead Sponsor:
Chugai Pharmaceutical
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
20+ years
Phase:
PHASE2
Brief Summary
To investigate the efficacy, safety, and pharmacokinetics when R435 and paclitaxel are administered concomitantly to patients with metastatic breast cancer.
Eligibility Criteria
Inclusion
- At least 20 years old and obtained a written informed consent
- Advanced breast cancer (StageⅣ) or Inoperable metastatic breast cancer
- HER2 negative
- At least one measurable lesion based on RECIST criteria
- No previous chemotherapy for metastatic breast cancer
Exclusion
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT00467012
Start Date
April 1 2007
End Date
September 1 2011
Last Update
April 26 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Kanto Region
Kanto, Japan
2
Kinki Region
Kinki, Japan
3
Kyushu region
Kyushu, Japan
4
Sikoku region
Sikoku, Japan